Cathie Wood Sells Rocket Lab Stock and Buys Intellia Therapeutics in Latest Trades

TLDR

• ARK sold 50,312 Rocket Lab shares worth ~$4 million through its ARKQ ETF on April 27
• This follows a sale of 113,000+ Rocket Lab shares the previous Friday
• ARK bought 263,848 Intellia Therapeutics shares worth ~$3.6 million across ARKK and ARKG
• ARK also sold 13,806 shares of Iridium Communications for ~$538,000
• Rocket Lab closed Monday up 3.28% at $82.29 despite the sell-off

Cathie Wood’s ARK Invest made several portfolio moves on Monday, April 27, 2026, according to the firm’s daily fund disclosures.

The biggest move was the sale of 50,312 shares of Rocket Lab through the ARKQ ETF, totaling around $4.01 million. This came just days after ARK sold over 113,000 shares of the same stock the previous Friday.

Rocket Lab USA, Inc., RKLB

That’s two rounds of selling in quick succession, suggesting ARK is deliberately cutting its position in the aerospace company.

What makes the timing stand out is that Rocket Lab’s stock actually rose 3.28% on Monday, closing at $82.29. ARK was selling into strength, not weakness.

The firm appears to be taking profits ahead of Rocket Lab’s first quarter 2026 earnings report, which is scheduled for May 7, 2026.

Wall Street analysts expect Rocket Lab to report revenues of $189.65 million for the quarter, up 55% year-over-year. They also project a loss per share of $0.07, an improvement from the $0.12 loss per share in the same period last year.

ARK Doubles Down on Intellia Therapeutics

While trimming Rocket Lab, ARK was actively buying Intellia Therapeutics. The firm purchased 263,848 shares across its ARKK and ARKG ETFs, worth roughly $3.6 million.

Intellia is a gene-editing company, and its stock had fallen 4.33% on the day. ARK appears to have used that dip as a buying opportunity.

This fits a pattern for ARK, which often adds to positions during pullbacks in companies it views as long-term growth plays.

ARK also sold 13,806 shares of Iridium Communications through its ARKX ETF, amounting to about $538,000. This continues a recent trend — ARK sold 33,315 Iridium shares the previous Friday and 81,422 shares the Monday before that.

Analyst View on Rocket Lab

Despite ARK’s selling, at least one Wall Street analyst remains bullish on Rocket Lab.

Stifel analyst Erik Rasmussen raised his price target on the stock to $105 from $90 and kept a Buy rating. He cited steady revenue growth, a strong project backlog, and the expected launch of the Neutron rocket later this year.

According to TipRanks, Rocket Lab currently holds a Moderate Buy consensus rating, based on nine Buy ratings and four Hold ratings over the past three months.

The average analyst price target sits at $89.00, implying about 8% upside from current levels.

ARK’s next daily disclosure will show whether the firm continued reducing its Rocket Lab position on Tuesday.

The post Cathie Wood Sells Rocket Lab Stock and Buys Intellia Therapeutics in Latest Trades appeared first on CoinCentral.